Market Place
Sourcing Support
Humanigen mulls bankruptcy after reverse merger falls through
25 Jul 2023 //
FIERCE BIOTECH
Humanigen Reports Second Quarter 2022 Financial Results
12 Aug 2022 //
BUSINESSWIRE
Humanigen`s stock sinks as COVID-19 prospect flunks NIH trial
14 Jul 2022 //
FIERCEBIOTECH
Humanigen Announces Peer-Reviewed Publication in Thorax in COVID-19 Patients
06 Jul 2022 //
BUSINESSWIRE
NIH/NIAID Locks ACTIV-5/BET-B Database
30 Jun 2022 //
BUSINESSWIRE
Humanigen Enters into Agreement with PCI Pharma Services in the UK
16 Jun 2022 //
BUSINESSWIRE
Humanigen Announces Participation and Presentation at Multiple Conferences
03 Jun 2022 //
BUSINESSWIRE
Humanigen Announces Participation and Presentation at H.C. Wainwright Conference
24 May 2022 //
BUSINESSWIRE
Humanigen Reports First Quarter 2022 Financial Results
05 May 2022 //
BUSINESSWIRE
Humanigen Announces Peer-Reviewed Publication on Benefits of Lenzilumab
19 Apr 2022 //
BUSINESSWIRE
Humanigen to Present and Participate at Multiple Investor Events in March
25 Feb 2022 //
BUSINESSWIRE
Humanigen lanceert managed access program (MAP) voor lenzilumab
11 Feb 2022 //
BUSINESSWIRE
Humanigen Launches Managed Access Program for Lenzilumab
09 Feb 2022 //
BUSINESSWIRE
Humanigen and Cenexi Announce Collaboration to Manufacture Lenzilumab in France
08 Feb 2022 //
BUSINESSWIRE
Humanigen: Peer-Reviewed Publication in The Journal of Medical Economics
18 Jan 2022 //
BUSINESSWIRE
Humanigen Aligns with FDA on Phase 3 Study for Lenzilumab with CAR-T
10 Jan 2022 //
BUSINESSWIRE
Humanigen Hits Target Enrollment in Phase 2/3 ACTIV-5/BET-B Trial of Lenzilumab
05 Jan 2022 //
BUSINESSWIRE
Lenzilumab Treatment Response Correlates with C-Reactive Protein Levels
03 Jan 2022 //
BUSINESSWIRE
The Lancet Publishes Peer-Reviewed Paper on Positive Phase 3 Lenzilumab Results
01 Dec 2021 //
BUSINESSWIRE
Humanigen Announces Clinical Trial Collaboration to Evaluate Lenzilumab
11 Nov 2021 //
BUSINESSWIRE
Humanigen Announces Release of Abstracts at ASH
05 Nov 2021 //
BUSINESSWIRE
EC Selects Lenzilumab as One of the 10 Most Promising Treatments for COVID-19
26 Oct 2021 //
BUSINESSWIRE
First Patient Dosed in Phase 2 Precision Medicine Study of Lenzilumab in CMML
26 Oct 2021 //
BUSINESSWIRE
Humanigen announces preparation of Phase 1b study of ifabotuzumab solid tumors
22 Oct 2021 //
BUSINESSWIRE
Humanigen Elects John Hohneker and Kevin Xie to Board of Directors
20 Oct 2021 //
BUSINESSWIRE
Humanigen’s Budget Impact Model Demonstrates Lenzilumab’s +ve Economic Value
11 Oct 2021 //
BUSINESSWIRE
Humanigen Signs Contract With Clinigen for Lenzilumab Managed Access Program
08 Oct 2021 //
BUSINESSWIRE
EMA Appoints officials for Humanigen`s planned submission of MAA for Lenzilumab
28 Sep 2021 //
BUSINESSWIRE
Humanigen Stock Craters After FDA Rejects COVID-19 Therapeutic
09 Sep 2021 //
BIOSPACE
Humanigen crashes as FDA shoots down its Covid-19 drug EUA
09 Sep 2021 //
ENDPTS
U.S. FDA declines emergency use approval for Humanigen`s COVID-19 drug
09 Sep 2021 //
REUTERS
Humanigen Reports Second Quarter 2021 Financial Results
12 Aug 2021 //
BUSINESSWIRE
Lenzilumab Treatment May Provide Enhanced Likelihood of Survival
04 Aug 2021 //
BUSINESSWIRE
Humanigen’s Partner in South Korea Receives MFDS Approval of Lenzilumab Study
23 Jul 2021 //
BUSINESSWIRE
UK MHRA accepts Humanigen’s submission of lenzilumab
12 Jul 2021 //
PHARMABIZ
UK MHRA accepts Humanigen’s submission of lenzilumab
12 Jul 2021 //
PHARMABIZ
UK MHRA accepts Humanigen’s submission of lenzilumab for marketing authorization
12 Jul 2021 //
PHARMABIZ
U.K. regulator accepts Humanigen`s COVID drug for speedy review
10 Jul 2021 //
FIERCEBIOTECH
U.K. regulator accepts Humanigen`s COVID drug for speedy review
09 Jul 2021 //
FIERCEBIOTECH
Humanigen begins submission of marketing authorization to UK MHRA for lenzilumab
15 Jun 2021 //
PHARMABIZ
Humanigen Starts Submission for Lenzilumab Marketing Authorization in COVID-19
14 Jun 2021 //
BUSINESSWIRE
Humanigen seeks U.K. authorization for COVID-19 therapy
14 Jun 2021 //
FIERCEBIOTECH
Humanigen Initiates Submission for Lenzilumab Marketing Authorization in COVID19
14 Jun 2021 //
BUSINESSWIRE
Humanigen Appoints Ken Trbovich as Senior Vice President, Investor Relations
07 Jun 2021 //
BUSINESSWIRE
Humanigen Submits Application to FDA for EUA for Lenzilumab
28 May 2021 //
BUSINESSWIRE
GM-CSF Gene-Edited CAR-T Data to be Presented at International Society
26 May 2021 //
BUSINESSWIRE
Humanigen Announces Publication of Results From Phase 3 Randomized Double-Blind
06 May 2021 //
BUSINESSWIRE
Humanigen Reports Positive Data With Lenzilumab in the ZUMA-19 CAR-T
19 Apr 2021 //
BUSINESSWIRE
Humanigen Announces Positive Results From Phase 1 Study of Ifabotuzumab
08 Apr 2021 //
BUSINESSWIRE
Humanigen Announces Closing of Public Offering of Common Stock
06 Apr 2021 //
BUSINESSWIRE
Humanigen Announces Pricing of Public Offering of Five Million Shares
30 Mar 2021 //
BUSINESSWIRE
Humanigen Announces Pricing of Public Offering of Five Million Shares
30 Mar 2021 //
BUSINESSWIRE
Humanigen Reports Positive Phase 3 Topline Results Demonstrating Lenzilumab™
29 Mar 2021 //
BUSINESSWIRE
Humanigen’s lenzilumab improves survival in hospitalised Covid-19 patients
29 Mar 2021 //
PHARMACEUTICAL-TECHNOLOGY
Humanigen to Host Conference Call to Report Phase 3 of LenzilumabTM
29 Mar 2021 //
BUSINESSWIRE
Humanigen Announces $80 Million Loan Facility from Hercules Capital
10 Mar 2021 //
BUSINESSWIRE
Humanigen Expands its anti-GM-CSF Patent Portfolio
02 Mar 2021 //
BUSINESSWIRE
Humanigen and Avid Bioservices Enter Into cGMP Manufacturing Agreement
03 Feb 2021 //
BUSINESSWIRE
Humanigen Completes Enrollment in Phase 3 Study of Lenzilumab in Hospitalized
29 Jan 2021 //
BUSINESSWIRE
Humanigen Completes Enrollment in Phase 3 Study of Lenzilumab
29 Jan 2021 //
BUSINESSWIRE
